Inhibition of gasdermin D-dependent pyroptosis attenuates the progression of silica-induced pulmonary inflammation and fibrosis

Meiyue Song,Jiaxin Wang,Youliang Sun,Junling Pang,Xiaona Li,Yuan Liu,Yitian Zhou,Peiran Yang,Tianhui Fan,Ying Liu,Zhaoguo Li,Xianmei Qi,Baicun Li,Xinri Zhang,Jing Wang,Chen Wang
DOI: https://doi.org/10.1016/j.apsb.2021.10.006
IF: 14.903
2022-03-01
Acta Pharmaceutica Sinica B
Abstract:Silicosis is a leading cause of occupational disease-related morbidity and mortality worldwide, but the molecular basis underlying its development remains unclear. An accumulating body of evidence supports gasdermin D (GSDMD)-mediated pyroptosis as a key component in the development of various pulmonary diseases. However, there is little experimental evidence connecting silicosis and GSDMD-driven pyroptosis. In this work, we investigated the role of GSDMD-mediated pyroptosis in silicosis. Single-cell RNA sequencing of healthy and silicosis human and murine lung tissues indicated that GSDMD-induced pyroptosis in macrophages was relevant to silicosis progression. Through microscopy we then observed morphological alterations of pyroptosis in macrophages treated with silica. Measurement of interleukin-1<i>β</i> release, lactic dehydrogenase activity, and real-time propidium iodide staining further revealed that silica induced pyroptosis of macrophages. Additionally, we verified that both canonical (caspase-1-mediated) and non-canonical (caspase-4/5/11-mediated) signaling pathways mediated silica-induced pyroptosis activation, <i>in vivo</i> and <i>in vitro</i>. Notably, <i>Gsdmd</i> knockout mice exhibited dramatically alleviated silicosis phenotypes, which highlighted the pivotal role of pyroptosis in this disease. Taken together, our results demonstrated that macrophages underwent GSDMD-dependent pyroptosis in silicosis and inhibition of this process could serve as a viable clinical strategy for mitigating silicosis.
pharmacology & pharmacy
What problem does this paper attempt to address?